TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Corporate Logo

Change of 11.92% for Tracon Pharmaceuticals Inc (NASDAQ:TCON)’s shorted shares was showed. It was announced in December by FINRA the 205,700 shorted shares on TCON. The up change of 11.92% from 183,800 shares was reported. Former TCON’s position will need 2 days to restore. It has 119,900 average volume. 1.42% is Tracon Pharmaceuticals Inc float short.

The stock decreased 3.23% or $0.04 during the last trading session, touching $1.2.TRACON Pharmaceuticals, Inc. has volume of 21,218 shares. Since December 7, 2017 TCON has declined 34.33% and is downtrending. TCON underperformed the S&P 500 by 49.95%.

TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration , and fibrotic diseases.The company has $35.85 million market cap. The Company’s lead product candidate is TRC105, an endoglin antibody, which is in Phase III clinical trials for angiosarcoma; randomized Phase II clinical trials for renal cell carcinoma; Phase II clinical trials for soft tissue sarcoma; Phase II clinical trials for gestational trophoblastic neoplasia; Phase I/II clinical trials for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trials for breast cancer; and Phase I/II clinical trials for wet AMD.Last it reported negative earnings. The companyÂ’s other product candidates comprise TRC102, a small molecule that is in Phase II clinical trials for mesothelioma, Phase II clinical trials for glioblastoma, Phase I clinical trial for solid tumors and lymphomas, as well as Phase I clinical trial for lung cancer; and TRC253, a small molecule high affinity competitive inhibitor of wild type androgen receptor (AR) and multiple AR mutant receptors that is in Phase I/II clinical trials for the treatment prostate cancer.

For more TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) news released briefly go to:,,, or The titles are as follows: “TRACON Pharmaceuticals Announces Completion of Enrollment in Randomized Phase 2b TRAXAR Study of TRC105 and Inlyta® in Renal Cell Carcinoma – GlobeNewswire” released on September 07, 2017, “Daily Biotech Pulse: Clinical Hold Lifted Off Crispr’s Gene-Edited Therapy, Endra To Offer Shares – Benzinga” on October 11, 2018, “TRACON Pharmaceuticals Announces $21 Million Common Stock Purchase Agreement with Aspire Capital Fund, LLC – GlobeNewswire” with a publish date: March 14, 2017, “Close Update: Wall Street Extends Trump-Rally to New Record Highs – Nasdaq” and the last “Tracon Pharmaceuticals: Capitalizing On Blockbuster VEGF Market – Seeking Alpha” with publication date: August 22, 2016.

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *